Home
/ Orexo
/ Competitors

Orexo Competitors and Similar CompaniesClear all

Orexo's competitors and similar companies include Active Biotech, Curadis, Imvax and Agios Pharmaceuticals.

	Orexo Orexo, a specialty pharmaceutical company, engages in the development and commercialization of drugs.	Active Biotech Active Biotech is a biotechnology company with a focus on neurodegenerative and inflammatory diseases and cancer.	Curadis Curadis is a company that develops medicines and therapy concepts for the treatment of hormone-dependent diseases and cancer.	Imvax Imvax is a biotechnology company that develops vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.
Founding Date	Founding Date 1995	Founding Date 1998	Founding Date 2015	Founding Date 2015	Founding Date 2008
Type	Type Public	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare drug development oncology pharma pharmacy	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare drug development oncology pharmacy	Tags Healthcare drug development oncology pharmacy	Tags Healthcare drug development oncology pharma
Locations	Locations Uppsala, SE HQ Uppsala, SE Morristown, US	Locations Lund, SE HQ Lund, SE	Locations Erlangen, DE HQ	Locations Philadelphia, US HQ	Locations Cambridge, US HQ
Employees	Employees 110	Employees 517% decrease	Employees 2	Employees 2723% decrease	Employees 53611% increase
Valuation ($)	Valuation ($) 36.3 m	Valuation ($) 21 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 2.7 b
Financial
Revenue (est.)	Revenue (est.) kr26m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $54m (FY, 2025)
Cost of goods	Cost of goods kr14.5m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $6.3m (FY, 2025)
Gross profit	Gross profit kr18m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $47.7m (FY, 2025)
Net income	Net income (kr403.3m) (FY, 2025)	Net income (kr37.3m) (FY, 2025)	Net income N/A	Net income N/A	Net income ($412.8m) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 72.9m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 166.7m	Total funding raised N/A